Sunlight, which is required for vitamin D biosynthesis, may be protective in multiple
sclerosis (MS), due to the immunoregulatory functions of 1,25-dihydroxyvitamin D3
(1,25-(OH)2D3), the hormonally active vitamin D metabolite. This hypothesis provided
the impetus for the experiments reported here investigating mechanisms whereby 1,25-(OH)2D3
may inhibit murine experimental autoimmune encephalomyelitis (EAE). Severe EAE was
induced, 1,25-(OH)2D3 or mock treatment was administered, and clinical disease, histopathological
disease, and encephalitogenic cells in the central nervous system (CNS) were analyzed
within 24-72 h of the treatment. The mock-treated mice remained paralyzed (stage 3
EAE) while most hormone-treated animals regained the partial use of both hind limbs
(stage 2 EAE) within 72 h of treatment. A histopathological examination showed the
hormone-treated mice had a 50% decrease in white matter and meningeal inflammation
at 72 h post treatment. A flow cytometric analysis of cell surface markers on spinal
cord cells recovered 24 h post treatment showed the mock-treated mice with EAE had
about 7.0 +/- 2.3 million Mac-1+ cells/cord, whereas the hormone-treated mice had
about 2.1 +/- 2.6 million Mac-1+ cells/cord, which was not significantly different
from the unmanipulated control mice. Otherwise, the flow cytometric analysis detected
no significant differences between the groups with respect to CD4+ or CD8+ T cells
or B cells or macrophages in draining lymph nodes or spinal cords. These results are
discussed with regard to possible fates for the 5 million Mac-1+ cells that were rapidly
lost from the inflamed CNS in the 1,25-(OH)2D3-treated mice, and the possible beneficial
effect of hormone treatment in resolving acute MS.